Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daniel Raynor Insider Profile
4 Followers
Daniel Raynor, Director at ANI Pharmaceuticals, holds 289.00K shares in ANI Pharmaceuticals (Ticker: ANIP). Most recently, Daniel Raynor Sold $7,215 shares of ANI Pharmaceuticals on Mar 19, 2018 for an estimated value of 439.05K.
Profitable Transactions
1 out of 5 Profitable Transactions
Average Return
-24.80%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Daniel Raynor holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Mar 16, 2015 - Mar 16, 2016
Return:+50.00%
The most profitable trade made by Daniel Raynor
Daniel Raynor's Trading History
List of latest transactions for each holding click on a transaction to see Daniel Raynor's performance on stock
You May Also Like
Daniel Raynor insider profile FAQ
What is the percentage of profitable transactions made by Daniel Raynor?
The percentage of profitable transactions made by Daniel Raynor is 20%.
What is the average return per transaction made by Daniel Raynor?
The average return per transaction made by Daniel Raynor is -24.80%.
What stocks does Daniel Raynor hold?
Daniel Raynor holds: ANIP stocks.
What was Daniel Raynor’s latest transaction?
Daniel Raynor latest transaction was an Informative Sell of $439.05K.
What was Daniel Raynor's most profitable transaction?
Daniel Raynor’s most profitable transaction was an Informative Sell of ANIP stock on March 16, 2015. The return on the trade was 50.00%.
What is Daniel Raynor's role in ANI Pharmaceuticals?
Daniel Raynor's role in ANI Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.